Luminii provides CDD to Foresight on their recent investment into private healthcare company 352 Medical Group
Luminii Consulting is delighted to have provided Commercial Due Diligence (CDD) support to Foresight on their recent £5 million growth capital investment into Northern Ireland’s largest private healthcare business, 352 Medical Group Limited (“3fivetwo”).
The investment was made via a new fund managed by Foresight in partnership with 57 Stars, dedicated to investing in businesses with the potential to boost the economy of Northern Ireland.
The Company comprises principally of two private hospitals located in Belfast in Northern Ireland and Sligo in the Republic of Ireland. Founded in 2004 by NHS Consultant Obstetrician and Gynaecologist, Suresh Tharma, 3fivetwo began by providing services such as health screening, 3D obstetrics and gynaecology scanning. Since then the Company has grown significantly, first and foremost as a service provider for private patients and also as a provider of clinical outsourcing to the NHS.
The investment from Foresight will be used to increase theatre and ward capacity at both facilities, with a conversion of the theatres and a bed extension to the main wards planned to commence in 2019.
"Luminii Consulting is delighted to have supported Foresight on this transaction, this deal helps to further strengthen our credentials in the healthcare sector. We wish Foresight and 3fivetwo's Management team continued success for the future." - Lushani Kodituwakku, Managing Director, Luminii Consulting
Latest articles
- Luminii's Lushani Kodituwakku wins the Business/Entrepreneurship Award at the Women in Management (WIM) UK Professional & Career Women Awards 2024 19 Mar 2024
- Luminii provides CDD support to Gresham House Ventures on their investment in Azarc 05 Feb 2024
- Luminii provides CDD support to Octopus Ventures on their investment in VaultSpeed 21 Nov 2023
- Luminii's Lushani Kodituwakku named Market Research & Intelligence CEO of the Year 2023 by CEO Monthly 08 Nov 2023
- Luminii shortlisted as Commercial Due Diligence Provider of the Year at Unquote's British Private Equity Awards 2023 14 Sep 2023